The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hemophilia A

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hemophilia A


Psychiatry related information on Hemophilia A


High impact information on Hemophilia A


Chemical compound and disease context of Hemophilia A


Biological context of Hemophilia A


Anatomical context of Hemophilia A


Gene context of Hemophilia A


Analytical, diagnostic and therapeutic context of Hemophilia A


  1. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. Allain, J.P., Laurian, Y., Paul, D.A., Verroust, F., Leuther, M., Gazengel, C., Senn, D., Larrieu, M.J., Bosser, C. N. Engl. J. Med. (1987) [Pubmed]
  2. Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease. Gralnick, H.R., Rick, M.E. N. Engl. J. Med. (1983) [Pubmed]
  3. Myocardial infarction in a patient with hemophilia treated with DDAVP. Bond, L., Bevan, D. N. Engl. J. Med. (1988) [Pubmed]
  4. Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII). Ratnoff, O.D., Menitove, J.E., Aster, R.H., Lederman, M.M. N. Engl. J. Med. (1983) [Pubmed]
  5. An IgG autoantibody which inactivates C1-inhibitor. Jackson, J., Sim, R.B., Whelan, A., Feighery, C. Nature (1986) [Pubmed]
  6. The telomeric region of the human X chromosome long arm: presence of a highly polymorphic DNA marker and analysis of recombination frequency. Oberlé, I., Drayna, D., Camerino, G., White, R., Mandel, J.L. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  7. The high mortality of gastrointestinal bleeding in HIV-seropositive patients: a multivariate analysis of risk factors and warning signs of mortality in 50 consecutive patients. Cappell, M.S., Geller, A.J. Am. J. Gastroenterol. (1992) [Pubmed]
  8. Acute liver failure induced by alcohol and paracetamol in an HCV-infected haemophiliac. Leach, M., Makris, M., Gleeson, D.C., Preston, F.E. Br. J. Haematol. (1998) [Pubmed]
  9. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Bi, L., Lawler, A.M., Antonarakis, S.E., High, K.A., Gearhart, J.D., Kazazian, H.H. Nat. Genet. (1995) [Pubmed]
  10. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Picketts, D.J., Lillicrap, D.P., Mueller, C.R. Nat. Genet. (1993) [Pubmed]
  11. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. Schwartz, R.S., Abildgaard, C.F., Aledort, L.M., Arkin, S., Bloom, A.L., Brackmann, H.H., Brettler, D.B., Fukui, H., Hilgartner, M.W., Inwood, M.J. N. Engl. J. Med. (1990) [Pubmed]
  12. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. Nilsson, I.M., Berntorp, E., Zettervall, O. N. Engl. J. Med. (1988) [Pubmed]
  13. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. Salzman, E.W., Weinstein, M.J., Weintraub, R.M., Ware, J.A., Thurer, R.L., Robertson, L., Donovan, A., Gaffney, T., Bertele, V., Troll, J. N. Engl. J. Med. (1986) [Pubmed]
  14. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Pratt, K.P., Shen, B.W., Takeshima, K., Davie, E.W., Fujikawa, K., Stoddard, B.L. Nature (1999) [Pubmed]
  15. Expression of active human factor IX in transfected cells. Busby, S., Kumar, A., Joseph, M., Halfpap, L., Insley, M., Berkner, K., Kurachi, K., Woodbury, R. Nature (1985) [Pubmed]
  16. Key residues involved in calcium-binding motifs in EGF-like domains. Handford, P.A., Mayhew, M., Baron, M., Winship, P.R., Campbell, I.D., Brownlee, G.G. Nature (1991) [Pubmed]
  17. Impairment of hemostasis in patients with severe hemophilia. Failure of diphenhydramine, chlorpromazine, and guaifenesin. Buchanan, G.R., Handin, R.I. JAMA (1978) [Pubmed]
  18. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. Thompson, A.R. J. Clin. Invest. (1977) [Pubmed]
  19. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Chao, H., Mansfield, S.G., Bartel, R.C., Hiriyanna, S., Mitchell, L.G., Garcia-Blanco, M.A., Walsh, C.E. Nat. Med. (2003) [Pubmed]
  20. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Herzog, R.W., Yang, E.Y., Couto, L.B., Hagstrom, J.N., Elwell, D., Fields, P.A., Burton, M., Bellinger, D.A., Read, M.S., Brinkhous, K.M., Podsakoff, G.M., Nichols, T.C., Kurtzman, G.J., High, K.A. Nat. Med. (1999) [Pubmed]
  21. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Crossley, M., Brownlee, G.G. Nature (1990) [Pubmed]
  22. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Winkler, C., Modi, W., Smith, M.W., Nelson, G.W., Wu, X., Carrington, M., Dean, M., Honjo, T., Tashiro, K., Yabe, D., Buchbinder, S., Vittinghoff, E., Goedert, J.J., O'Brien, T.R., Jacobson, L.P., Detels, R., Donfield, S., Willoughby, A., Gomperts, E., Vlahov, D., Phair, J., O'Brien, S.J. Science (1998) [Pubmed]
  23. Factor VIII gene explains all cases of haemophilia A. Naylor, J.A., Green, P.M., Rizza, C.R., Giannelli, F. Lancet (1992) [Pubmed]
  24. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Manno, C.S., Arruda, V.R., Pierce, G.F., Glader, B., Ragni, M., Rasko, J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A., Kay, M.A. Nat. Med. (2006) [Pubmed]
  25. Immunologic studies in asymptomatic hemophilia patients. Relationship to acquired immune deficiency syndrome (AIDS). Landay, A., Poon, M.C., Abo, T., Stagno, S., Lurie, A., Cooper, M.D. J. Clin. Invest. (1983) [Pubmed]
  26. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Gangadharan, B., Parker, E.T., Ide, L.M., Spencer, H.T., Doering, C.B. Blood (2006) [Pubmed]
  27. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Hausl, C., Ahmad, R.U., Sasgary, M., Doering, C.B., Lollar, P., Richter, G., Schwarz, H.P., Turecek, P.L., Reipert, B.M. Blood (2005) [Pubmed]
  28. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Hausl, C., Ahmad, R.U., Schwarz, H.P., Muchitsch, E.M., Turecek, P.L., Dorner, F., Reipert, B.M. Blood (2004) [Pubmed]
  29. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Smith, M.W., Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Lomb, D.A., Goedert, J.J., O'Brien, T.R., Jacobson, L.P., Kaslow, R., Buchbinder, S., Vittinghoff, E., Vlahov, D., Hoots, K., Hilgartner, M.W., O'Brien, S.J. Science (1997) [Pubmed]
  30. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. d'Oiron, R., Lavergne, J.M., Lavend'homme, R., Benhida, A., Bordet, J.C., Negrier, C., Peerlinck, K., Vermylen, J., Saint-Remy, J.M., Jacquemin, M. Blood (2004) [Pubmed]
  31. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Denis, C.V., Kwack, K., Saffaripour, S., Maganti, S., André, P., Schaub, R.G., Wagner, D.D. Blood (2001) [Pubmed]
  32. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. van 't Veer, C., Hackeng, T.M., Delahaye, C., Sixma, J.J., Bouma, B.N. Blood (1994) [Pubmed]
  33. Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation. Boccia, L.M., Lillicrap, D., Newcombe, K., Mueller, C.R. Mol. Cell. Biol. (1996) [Pubmed]
  34. Prenatal diagnosis by linkage: hemophilia A and polymorphic glucose-6-phosphate deydrogenase. Edgell, C.J., Kirkman, H.N., Clemons, E., Buchanan, P.D., Miller, C.H. Am. J. Hum. Genet. (1978) [Pubmed]
  35. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Lin, Y., Chang, L., Solovey, A., Healey, J.F., Lollar, P., Hebbel, R.P. Blood (2002) [Pubmed]
  36. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Powell, J.S., Ragni, M.V., White, G.C., Lusher, J.M., Hillman-Wiseman, C., Moon, T.E., Cole, V., Ramanathan-Girish, S., Roehl, H., Sajjadi, N., Jolly, D.J., Hurst, D. Blood (2003) [Pubmed]
  37. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Chuah, M.K., Schiedner, G., Thorrez, L., Brown, B., Johnston, M., Gillijns, V., Hertel, S., Van Rooijen, N., Lillicrap, D., Collen, D., VandenDriessche, T., Kochanek, S. Blood (2003) [Pubmed]
WikiGenes - Universities